Neodyne Biosciences Data Now Published in Plastic & Reconstructive Surgery Shows Long-Term Effectiveness of the EMBRACE® Device in Reducing Scar Formation

MENLO PARK, Calif., Sept. 10, 2014 /PRNewswire/ -- Neodyne Biosciences announced today that favorable 1 year follow-up results from the pivotal multi-center, randomized, controlled trial of the embrace® Advanced Scar Therapy device (REFINE), were published in Plastic & Reconstructive Surgery, showing a highly significant improvement in scarring for patients treated with embrace® versus control.

"With over 80 million surgical procedures performed in the US each year, there is enormous patient demand for a device to effectively reduce scar formation. We are thrilled that data from this multi-center, randomized, controlled trial have been published in the journal of the American Society of Plastic Surgeons. The highly significant results validate the experiences we hear from patients every day," said Bill Beasley, President and COO of Neodyne Biosciences.

The embrace® device works by actively relieving the tension surrounding a scar to minimize scar formation. It uses technology initially developed at Stanford University and subsequently licensed to Neodyne Biosciences.

Highlights of the REFINE trial data include:

• Highly significant statistical difference between treated and control (p value < 0.02)
• Met Primary and Secondary endpoints vs. standard of care (Steri-Strips, Mederma, silicone gel, silicone sheeting)
• High level of patient and physician satisfaction
• High likelihood to recommend therapy by both physician and patient

In addition, both patients and investigators found that embrace-treated scars demonstrated significant improvements in overall appearance, irregularity, width and stiffness compared to the control-treated scar at 12 months.

The full text of the article can be found at: http://journals.lww.com/plasreconsurg/Fulltext/2014/09000/A_Randomized_Controlled_Trial_of_the_embrace.28.aspx 

About Neodyne Biosciences, Inc.
Neodyne Biosciences (www.neodynebio.com) is an evidence based company developing and commercializing innovative tissue repair devices to minimize scar formation, restoring both function and aesthetic appearance. The company is developing stress-shielding devices capable of controlling the mechanical wound environment to ameliorate post-surgical scarring. Although the etiology remains unclear, mechanical forces such as surrounding skin tension and body movement have been demonstrated to increase fibrosis and scar formation. It is estimated that approximately 80 million major surgical procedures are performed in the United States each year and 230 million performed worldwide. Patient frustration with post-surgical scarring spans a variety of procedures with many seeking means of prevention and treatment.

Neodyne Investor Relations Contacts:

SOURCE Neodyne Biosciences, Inc.